TIGIT/PVR轴调节血液恶性瘤中的抗瘤免疫力
Fanqiao Meng1, Maoyuan Xiang1, Yu Liu1
1Department of Hematology, Daping Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
Annals of hematology
|March 13, 2025
概括
TIGIT/PVR轴是血液恶性瘤的关键目标,阻碍了抗瘤免疫力. 针对这一轴提供了有前途的免疫疗法策略,以改善患者的生存率.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 癌症研究 癌症研究
背景情况:
- 血液性恶性瘤是具有高复发率的侵袭性癌症.
- 免疫疗法是这些癌症的关键治疗方法.
- 作为NK和T细胞上的抑制受体,TIGIT具有与PD-1相似的新型治疗标.
研究的目的:
- 审查血液恶性瘤中TIGIT/PVR轴的研究.
- 阐明TIGIT/PVR轴阻碍抗瘤免疫力的机制.
- 探索针对TIGIT/PVR轴的治疗策略.
主要方法:
- 关于TIGIT/PVR轴的当前研究的文献综述.
- 通过TIGIT/PVR轴介导的免疫逃避机制的分析.
- 探索免疫治疗策略和组合疗法.
主要成果:
- TIGIT/PVR轴在编排瘤免疫力方面发挥着重要作用.
- 这个轴阻碍了血液恶性瘤中的抗瘤免疫反应.
- 向TIGIT目前正在临床试验中,并显示出潜在的潜力.
结论:
- 针对TIGIT/PVR轴是一个有前途的免疫治疗策略,用于血液恶性瘤.
- 涉及TIGIT抑制剂的组合疗法可能会提高治疗疗效.
- 需要进一步的研究来优化基于TIGIT的疗法,以改善患者的治疗结果.
相关概念视频
Tumor Immunotherapy
457
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
457
Regulation of Hematopoietic Stem Cells
3.1K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.1K
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
The Tumor Microenvironment
6.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K


